113
New Covid vaccines are on the way as 'Eris' variant rises
(www.reuters.com)
you are viewing a single comment's thread
view the rest of the comments
view the rest of the comments
this post was submitted on 14 Aug 2023
113 points (100.0% liked)
World News
22058 readers
35 users here now
Breaking news from around the world.
News that is American but has an international facet may also be posted here.
Guidelines for submissions:
- Where possible, post the original source of information.
- If there is a paywall, you can use alternative sources or provide an archive.today, 12ft.io, etc. link in the body.
- Do not editorialize titles. Preserve the original title when possible; edits for clarity are fine.
- Do not post ragebait or shock stories. These will be removed.
- Do not post tabloid or blogspam stories. These will be removed.
- Social media should be a source of last resort.
These guidelines will be enforced on a know-it-when-I-see-it basis.
For US News, see the US News community.
This community's icon was made by Aaron Schneider, under the CC-BY-NC-SA 4.0 license.
founded 2 years ago
MODERATORS
🤖 I'm a bot that provides automatic summaries for articles:
Click here to see the summary
NEW YORK, Aug 14 (Reuters) - A new COVID vaccine is due out next month, but health experts and analysts say it is likely to be coolly received even as hospitalizations from "Eris", a variant of the Omicron form of the coronavirus, rise around the country.Healthcare providers and pharmacies such as CVS Health (CVS.N) will start next month to offer the shot, updated to fight the Omicron version of the virus that has been dominant since last year.
They will be fighting declining concern about the virus, as well as fatigue and skepticism about the merits of this vaccine, Kaiser Family Foundation Director of Survey Methodology Ashley Kirzinger said.
As with the flu, Pfizer (PFE.N)/BioNTech SE (22UAy.DE), Moderna (MRNA.O) and Novavax (NVAX.O), have created versions of the COVID vaccine to try to match the variant they believe will be circulating this fall.
Dr. William Schaffner, an infectious diseases specialist at Vanderbilt University and a liaison to the CDC's Advisory Committee on Immunization practices, said it is possible that the ACIP could make a weaker recommendation for younger, healthier people.
Dr. David Boulware, an infectious diseases specialist at the University of Minnesota, said that according to research he has published, people who are boosted have less severe symptoms for a shorter duration.